NCT07532148 2026-04-15
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Chong Kun Dang Pharmaceutical
Phase 1 Not yet recruiting
Clinical Trials
14 trialsNCT05054751 2024-10-10
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3 Completed
NCT04500587 2024-09-19
Phase 1 First in Human Study of ZN-d5 as a Single Agent
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1 Completed
NCT05199337 2024-09-19
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05682170 2024-09-19
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 1/2 Terminated
NCT05189171 2024-06-28
MODEL-CRC
Xilis, Inc.
Completed
NCT05758610 2024-05-08
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Shengke Pharmaceuticals (Jiangsu) Limited, China
Phase 1 Recruiting
NCT04197986 2024-03-13
PROOF302
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04840784 2023-10-11
First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML
Shengke Pharmaceuticals (Jiangsu) Limited, China
Phase 1 Terminated
NCT06055348 2023-09-26
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT04972422 2021-09-05
A Phase 1b Study of ZN-c3 in Chinese Subjects
Zentera Therapeutics HK Limited
Phase 1 Unknown
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT03236974 2020-02-06
D6090C00002
AstraZeneca
Phase 1 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed